In the last three months, 4 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 2 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Intellia Therapeutics, presenting an average target of $48.25, a high estimate of $70.00, and a low estimate of $29.00. A decline of 8.39% from the prior average price target is evident in the current average.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of...
Login or create a forever free account to read this news
Sign up/Log in